Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-20
    E.g., 2018-07-20

Articles

51281 items
12:00 AM, Aug 24, 2000  |  BC Extra | Company News

PowderJect in talks with Celltech

PowderJect (LSE:PJP) is in talks with Celltech (LSE:CCH; CLL) to acquire CCH's Medeva Vaccines division. According to PJP, which specializes in needleless dry powder injection technology, the acquisition would create an integrated vaccines company, with...
12:00 AM, Aug 24, 2000  |  BC Extra | Financial News

Targacept raises $30.4 million

Targacept (Winston-Salem, N.C.) raised $30.4 million in a first round financing. Investors included Euclid SR; Burrill & Co; Auriga Vantures; CDC Innovation; Genavent; Societe Generale Asset Management Finance; Advent Venture Partners; and Longleaf Venture Fund....
12:00 AM, Aug 24, 2000  |  BC Extra | Financial News

Neurochem sells shoe

Neurochem (TSE:NRM) raised C$4.8 million (US$3.3 million) through the sale of 581,818 shares at C$8.25 authorized to cover overallotments in its June IPO. The sale brings to C$36.8 million (US$24.9 million) the total raised in...
12:00 AM, Aug 24, 2000  |  BC Extra | Clinical News

Alexion completes Phase II 5G1.1 enrollment

ALXN completed enrollment of 200 rheumatoid arthritis patients in its double-blind, placebo-controlled U.S. Phase II trial of 5G1.1. The trial is designed to assess safety and clinical efficacy of repeated dosing of the humanized antibody...
12:00 AM, Aug 24, 2000  |  BC Extra | Company News

Rigel and Novartis begin third discovery collaboration

Rigel (South San Francisco, Calif.) will use its combinatorial biology technology to identify small molecule targets to regulate lung epithelial cell function to treat diseases such as asthma and chronic obstructive pulmonary disease. Novartis (SWX:NOVN;...
12:00 AM, Aug 24, 2000  |  BC Extra | Company News

Draxis receives FDA approval

The FDA granted marketing approval to DRAX's Draximage Inc. subsidiary (Kirkland, Quebec) for its BrachySeed iodine-125 brachytherapy seed product to treat prostate cancer. BrachySeed received Canadian marketing approval in May....
12:00 AM, Aug 24, 2000  |  BC Extra | Company News

CollaGenex selects Taro as Israeli distributor

TARO subsidiary Taro International will market and distribute CGPI's Periostat, an enzyme inhibitor to treat periodontal disease, in Israel. TARO will be responsible for Israeli registration of Periostat, will pay milestones associated with the regulatory...
12:00 AM, Aug 24, 2000  |  BC Extra | Company News

Incyte signs distribution deals

INCY partnered with 19 companies in Asia, Europe, Latin America and the U.S. to market and distribute its custom genomics technologies, including its LifeSeq Gene-by-Gene sets of clone reagents and related sequence data....
12:00 AM, Aug 24, 2000  |  BC Extra | Company News

Cubist to evaluate Xenogen technology

Xenogen (Alameda, Calif.) granted CBST an evaluation license to its real-time in vivo imaging technology, which assesses new chemical entities by detecting fluorescent or bioluminescent cells in living animals. CBST will assess the technology in...
12:00 AM, Aug 24, 2000  |  BC Extra | Company News

Phylos progress in Amgen deal

Under its drug discovery collaboration with AMGN, Phylos said it used its PROfusion peptide and protein selection technology to identify high-affinity binding agents to certain AMGN therapeutic targets. The discovery triggered an undisclosed milestone to...

Pages